APR 24, 2019 5:14 PM PDT

Nanomachine Improves Drug Delivery for Cancer Therapeutics

WRITTEN BY: Nouran Amin

Recent studies on mice has allowed researchers to find a way to deliver specific drugs to certain parts of the body that are exceptionally difficult to access. Specifically, they created a nanomachine called Y-shaped block catiomer (YBC) that can bind to certain therapeutic materials forming a package of 18 nanometers wide—small enough to pass through the tight barriers in cancers of the brain or pancreas. The studies could ultimately advance the fight against cancer.

Learn about nucleic acids:

Although there are other promising treatments for cancer, such as gene therapy, which involves the injection of a nucleic acid-based drug into the bloodstream -- typically small interfering RNA (siRNA) – the nucleic acid needs to be protected within a nanoparticle or it can degrade before reaching its target.

"siRNA can switch off specific gene expressions that may cause harm. They are the next generation of biopharmaceuticals that could treat various intractable diseases, including cancer," explained Associate Professor Kanjiro Miyata of the University of Tokyo, who jointly supervised the study. "However, siRNA is easily eliminated from the body by enzymatic degradation or excretion. Clearly a new delivery method was called for."

The Y-shaped block catiomer is two component molecules of polymeric materials connected in a Y-shape. It has several sites of positive charge that bind to negative charges in siRNA.

Laser scanning microscope images of blood vessels in a mouse following treatment. Credit: © 2019 Kanjiro Miyata

"We used polymers to fabricate a small and stable nanomachine for the delivery of siRNA drugs to cancer tissues with a tight access barrier," said Miyata. "The shape and length of component polymers is precisely adjusted to bind to specific siRNAs, so it is configurable. The most surprising thing about our creation is that the component polymers are so simple, yet uPIC is so stable. It has been a great but worthy challenge over many years to develop efficient delivery systems for nucleic acid drugs. It is early days, but I hope to see this research progress from mice to help treat people with hard-to-treat cancers one day."

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 15, 2022
Drug Discovery & Development
First Drug for Sleep Apnea Shows Promise in Patients
APR 15, 2022
First Drug for Sleep Apnea Shows Promise in Patients
A new drug for sleep apnea could reduce breathing pauses during sleep by over 20 per hour. The corresponding study was p ...
JUN 06, 2022
Drug Discovery & Development
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
JUN 06, 2022
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific sat down with Sheng Li, PhD, Program Manager, to speak about our rapid service for small-scal ...
MAY 19, 2022
Drug Discovery & Development
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
MAY 19, 2022
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
An antibiotic known as clofoctol has shown promise in treating SARS-CoV-2 in mice. The corresponding study was published ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 09, 2022
Cancer
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
JUN 09, 2022
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive pancreatic cancer with limited treatment options.  PDA ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
Loading Comments...